Clinical Trial Search

Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants

Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects

Primary: Event-free Survival (EFS) — 83 percentage of not experiencing EFS event

Primary: Overall Response (OR) Rate — 0.07 Proportion of participants

Primary: Progression-free Survival — 72 Percent

Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants

Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants

Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Number of Participants (Par.) Receiving TST and I 131 TST With a Response >=30 Days Versus Par. With a Response >=30 Days After Their Last Qualifying Chemotherapy…

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Percentage of Participants With a Complete Remission (CR) or Partial Remission (PR) — 39.5 percentage of participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients

Primary: Number of Participants (Par.) With Confirmed Response as Assessed by the Investigator — 21; 8 participants

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Maximum Tolerated Dose of Lenalidomide (Phase I) — 10 milligrams PO daily

Primary: Overall Response Rate (ORR) — 0.05 Proportion of participants

Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants

Primary: Progression Free Survival Probability at 12-month Post HCT — 0.80 probability

Primary: Overall Response Rate (ORR) — 80.3 Percent of Participants — p=<.0001

Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients

Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants

Primary: Number of Participants With Objective Response — 9 participants

Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005

Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants

Primary: Participants With Adverse Events — 0; 15; 15 percentage of participants

Primary: 2-Year Progression-Free Survival — 71 Percentage of Participants (%)